A collaborative effort to engineer a dual knock-in reporter system to simultaneously broadcast aberrant stem cell and differentiation activity in colorectal cancer for discovery science. @JunQiLab @fonlikk @paulthekid_ @zxli_phd nature.com/articles/s41467-0…

A wonderful study to be part of. Thanks for including us @ohyilmaz!

Now out in @ScienceMagazine! What gives some colorectal cancer cells the ability to spread? We found that ceramides made by cancer cells help activate a reparative program to metastasize. @qiming_kelly @ohyilmaz @Aslan_Tasdogan @UpasanaDA @aburakyildiz science.org/doi/10.1126/scie…

Very relevant finding for folks using CRISPRi in iPSC-derived neurons from @ophirshalem & team.

Finishing your PhD or looking for a post-bac research position? We’re recruiting multiple postdocs and research technicians to study somatic evolution! Come do interdisciplinary science in a friendly, collaborative environment at @harvardmed Genetics. naxerova.hms.harvard.edu/con…

Zenocutuzumab offers a new targeted treatment option for patients with previously treated, advanced NRG1 fusion-positive cholangiocarcinoma. @DanaFarber's James Cleary, MD, PhD, discusses in @OncLearnNetwork the approval and the role of comprehensive molecular testing. bit.ly/4h0u3Wy

Advanced fellowship in leukemia @DanaFarber for 2027-2028, application is open. jobcenter.hematology.org/job…

Please repost! We are seeking #PostDocs to join our lab in @YaleGenetics @YaleCancer @CancerYale to study #genetic and #host drivers of #PancreaticCancer and #LungCancer. Check out our newly updated website for more lab details! medicine.yale.edu/lab/muzumd…

A well-argued perspective on how developmental context influences cancer biology. It highlights why understanding the cell state in which transformation occurs can be as important as the mutations themselves.

FDA approval in cholangiocarcinoma: The FDA has approved zenocutuzumab for NRG1+ Cholangiocarcinoma. @DanaFarber's @JamesClearyMD helped lead research of the drug in this rare cancer type which has had limited treatment options. ➡️bit.ly/4dlQ8vg

My department at Oxford is recruiting junior faculty to the Ludwig Institute for Cancer Research. A collaborative and stimulating department, with great access to the breadth of the Oxford environment. The positions come with core funding and cutting edge technologies. If interested, apply here: shorturl.at/1ggGt

We asked early career scientists what they need: funding access, grant writing support, and mentorship. @theNCI listened. We're launching a trans-institute training initiative to deliver exactly that. Learn more. cancer.gov/grants-training/n…

#GI26 Our study underscores differing patient & physician perspectives on treatment trade-offs in 3L+ mCRC, particularly around #QOL and toxicity. Collaborative effort w/ @TakedaOncology #patientadvocate @cagirlinchi @colontown @Colorectalman @coloncanada @thermofisher

We have already started using Cytotrace2. Great framework and tool when thinking about stem-like states and plasticity across cancers!

This is truly the perfect time to implement technology like this. We can accurately and swiftly annotate single cells based on their developmental potential with applications across biology and medicine. Excited to see this move ahead!

It is so exciting to see the final version of our collaborative work with @LabSethi. We found that blocking HDAC1/2 pushes CRC cells out of a stem-like state and into differentiation. We will work tother more to find novel therapeutic options for CRC. authors.elsevier.com/c/1m7oK…

BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 It started from my frustration with the depressing effect that the current publishing system has on the well-being of myself, my team, and pretty much every scientist I know (maybe you’ve noticed from my stupid jokes… :) I was exhausted of dealing with the huge delays, reviewers that can be abusive, and how arbitrary it all is. Unfortunately, the most important factors are often WHO your reviewers are and who YOU are... It’s clear we need alternatives or at least ways to improve the situation. So, together with a really special and talented team we worked to develop this idea into “qed” a platform where you can get CONSTRUCTIVE feedback on your own work or CRITICALLY assess other people’s papers. It can be a real difference maker if many of you join us (thousands have tried it already, but today we release a NEW and much stronger version ;) Let’s harness qed to put the power back in the scientists’ hands, to do, to read & to publish science on our own terms. I’m dying for you to TRY IT, and it’s very simple - just drop a paper (the link to the website is in the replies👇) - it’s completely secure, private, and free, and you get results fast. Please show your support, SHARE, tell your friends, and let’s be the revolution 🫵!

We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]